News

Paul W. Noble, M.D., of Cedars-Sinai in Los Angeles, and Paul Frohna, M.D., Ph.D., of Endeavor BioMedicines, discussed the symptoms, epidemiology diagnosis and treatment of idiopathic pulmonary fibrosis (IPF) in a Managed Healthcare Executive K-Cast video series.

Luke Greenwalt, MBA, vice president and lead, IQVIA Market Access Center of Excellence, has joined the editorial advisory board of Managed Healthcare Executive.

Artificial intelligence is quickly becoming a valuable tool in the U.S. healthcare industry. Experts say a thoughtful approach can head off ethical problems and optimize efficiency.

Although many women are living longer after a breast cancer diagnosis, inequalities persist.

Dry eye disease affects up to 15% of the U.S. population and is one of the largest markets in the ophthalmology field.

Payers and providers are figuring out ways to overcome the transportation barriers that get in the way of people receiving healthcare.

Sean M. Oser, M.D., M.P.H., an associate professor in the Department of Family Medicine at the University of Colorado School of Medicine, discussed diabetes management and quality measures in a Managed Healthcare Executive K-Cast video series.

Previous research has shown an association between atopic dermatitis and obesity. But these findings elaborate on that observation and point to a connection to abnormal lipid metabolism and elevated "bad" LDL cholesterol levels.

Preclinical data had suggested reducing serotonin might improve symptoms of pulmonary arterial hypertension, but new phase 2b data suggest the opposite.

Less than a quarter of menopausal women have their menopause symptoms entered into their charts at primary care visits, resulting in missed opportunities for timely treatment.

Treatment with Entyvio (vedolizumab), an integrin receptor antagonist, followed by Humira (adalimumab), a tumor necrosis factor blocker, resulted in the lowest overall incidence of adverse events, according to an industry-sponsored study.

Sen. J.D. Vance credited Donald Trump with "salvaging" the Affordable Care Act (ACA). Gov. Tim Walz said Trump worked to repeal the ACA and Vance has proposals that would bring back pre-ACA limitations on health insurance for people with preexisting conditions.

With this year's Breast Cancer Awareness Month now underway, we are sharing eight facts and updates about breast cancer that you might not know about.

In 2025, Aetna will merge its three stand-alone prescription drug plans into a single plan and member cost-shares will be consistent at every pharmacy within its network.

Otulfi is the fourth Stelara biosimilar to be approved by the FDA.

Most people haven’t heard of the condition, but Friedreich’s ataxia is getting more attention because of a new treatment and a large number of clinical trials enrolling people with the condition.

Here’s what you missed this week on Managed Healthcare Executive.

The Democrats have expanded the program under the Affordable Care Act. Republicans have proposed cuts in federal funding and work requirements.

Neither party wants to be perceived as threatening the overall Medicare program. The Biden administration did take steps to reduce payment to Medicare Advantage plans. Insurance companies objected, but some industry observers said it was an overdue correction.

Employment satisfaction, sleep quality and lack of physical movement were all tied to vitality levels, survey results show.

The Phase I/II trials for rare forms of hereditary blindness further confirmed the potential for gene therapy treatments of congenital diseases of the retina.

The patient panels of physicians underrepresented in medicine (URiM) showed that they had greater odds of being a Medicaid provider than White family physicians.

Aqneursa is the second drug approved within a week to treat Niemann-Pick Disease, Type C.

A study found omitting a course of antibiotic prophylaxis was non-inferior to the routinely administering antibiotics in patients undergoing allogeneic hematopoietic stem cell transplantation.

Novo Nordisk said it’s open to discussions with PBMs based on their commitments that a lower semgalutide list price would not impact formulary coverage.

The FDA has already approved Zoryve cream (0.3% and 0.15%) for plaque psoriasis and atopic dermatitis in adults and children ages 6 and up. Currently, Zoryve foam 0.3% is only approved to treat seborrheic dermatitis in adult and pediatric patients 9 years and older.

This is the first FDA approved medication for the rare and progressive neurodegenerative disease, Niemann-Pick Disease Type C.

Bimzelx was first approved last year for the treatment of moderate to severe psoriasis in adults, making it the first and only IL-17A and IL-17F inhibitor approved in the United States for four autoimmune diseases.